Venus Remedies opens global fulfillment centre in Punjab

IMT News Desk
IMT News Desk
· 2 min read

Venus Global Fulfillment Center (VGFC) operates in full compliance with global pharmaceutical standards and can process up to 10,000 orders per day across B2B and B2C channels

Venus Remedies has inaugurated its state-of-the-art Venus Global Fulfillment Center (VGFC) in Mohali, Punjab. Spanning 132,000 square feet with a built-up area of 66,000 square feet, the facility is designed to significantly enhance the company’s global logistics and supply chain capabilities.

Built to meet international standards including WHO GDP, EU GMP, PAHO, CDSCO, GDP AEO, and ISO certifications, the VGFC ensures product integrity, quality compliance, and timely access to medicines across regulated and semi-regulated markets.

The centre can process up to 10,000 orders per day across B2B and B2C channels, with current utilization at approximately 30,000 orders per month. Its infrastructure includes temperature-controlled storage, RFID and barcode-based tracking, and automated sorting and retrieval systems. With capacity for more than 5,000 pallets and storage for over 50 million product units, VGFC is equipped to support dynamic global demand while maintaining precision and reliability.

“The VGFC represents a strategic advancement in our global supply framework,” said Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre. “It enhances our responsiveness to urgent healthcare needs and supports uninterrupted patient access across over 100 countries.”

Aditi K Chaudhary, President, International Business, Venus Remedies, added, “Every process within VGFC has been designed for speed, transparency, and consistency. From inventory management to final dispatch, the focus is on ensuring that every shipment meets the highest benchmarks of quality and reliability.”

Peeyush Jain, Deputy Managing Director and Head of Supply Chain, Venus Remedies, said, “The VGFC is built to bring greater resilience and agility to our global supply chain. By combining automation with skilled human oversight, we can process large order volumes with high precision while maintaining full regulatory compliance. This facility strengthens our ability to anticipate and respond to market needs efficiently, ensuring that critical medicines reach patients on time, every time.”

Read Next

Menthra launches Menthra Care in India, the human layer that turns everyday support into real continuity of care
News
July 17, 2026

Menthra launches Menthra Care in India, the human layer that turns everyday support into real continuity of care

Menthra, an AI-powered emotional wellbeing platform, today announced the launch of Menthra Care in India, expanding its platform to connect users with verified therapists, coaches, licensed clinical professionals and care organisations when they need support beyond an AI companion. The launch follows Menthra’s India debut in June, which saw tens of thousands of users join […]
Article by: IMT News Desk
IHH FutureHealth Now 2026 Explores How Affordability, AI and Precision Medicine Will Shape the Future of Care
News
July 17, 2026

IHH FutureHealth Now 2026 Explores How Affordability, AI and Precision Medicine Will Shape the Future of Care

Against a backdrop of geopolitical uncertainty, supply chain disruptions and rapid advances in artificial intelligence (AI) and precision medicine, FutureHealth.Now provided a platform for industry leaders to explore how innovation, technology and new models of care can help tackle rising healthcare costs, workforce pressures and growing demand for services across the region. At his opening […]
Article by: IMT News Desk
Novo Nordisk Wins EU Approval for Wegovy Weight-Loss Pill
News
July 16, 2026

Novo Nordisk Wins EU Approval for Wegovy Weight-Loss Pill

Novo Nordisk has secured European Commission approval for its once-daily Wegovy pill, giving the Danish drugmaker a major boost in the fast-growing obesity-treatment market. The approval makes it the first oral GLP-1 weight-loss treatment cleared in the European Union for adults with obesity or overweight who also have at least one weight-related health condition. The […]
Article by: IMT News Desk
Sun Pharma Wins South Africa Approval to Launch Generic Ozempic
News
July 16, 2026

Sun Pharma Wins South Africa Approval to Launch Generic Ozempic

India’s Sun Pharmaceutical Industries has received approval from South Africa’s health regulator to manufacture and sell a generic version of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, expanding its presence in the fast-growing GLP-1 market. The South African Health Products Regulatory Authority’s clearance allows Sun Pharma to market the injectable treatment for […]
Article by: IMT News Desk